HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

4-fluoro-N-indan-2-yl-benzamide

nitric oxide synthase transcription enhancer that ameliorates portal hypertension

Also Known As:

AVE 9488; AVE-9488; AVE9488

Networked: 7 relevant articles (2 outcomes, 1 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Organic Chemicals: 133

Experts

1.	Bauersachs, Johann: 3 articles (04/2009 - 01/2008)
2.	Ertl, Georg: 2 articles (04/2009 - 08/2008)
3.	Fraccarollo, Daniela: 2 articles (04/2009 - 08/2008)
4.	Ruetten, Hartmut: 2 articles (08/2008 - 05/2008)
5.	Widder, Julian D: 2 articles (08/2008 - 01/2008)
6.	Adamek, A: 1 article (11/2009)
7.	Bauersachs, J: 1 article (11/2009)
8.	Dienesch, C: 1 article (11/2009)
9.	Ertl, G: 1 article (11/2009)
10.	Fraccarollo, D: 1 article (11/2009)

Related Diseases

1.	Myocardial Infarction 04/01/2009 - "After experimental myocardial infarction, male Wistar rats were treated with either placebo or the eNOS-transcription enhancer, AVE9488 (25 ppm/day) for 10 weeks. " 01/01/2008 - "AVE9488, a novel eNOS transcription enhancer, attenuates cardiac remodeling and endothelial dysfunction in rats after large myocardial infarction. " 08/19/2008 - "Improvement in left ventricular remodeling by the endothelial nitric oxide synthase enhancer AVE9488 after experimental myocardial infarction." 08/19/2008 - "In this study, we investigated whether the transcription enhancer of endothelial NO synthase (eNOS) AVE9488 improves cardiac remodeling and heart failure after experimental myocardial infarction (MI). " 01/01/2008 - "AVE 9488, ACE or HMG-CoA reductase inhibition result in significant increases in EPC levels, and beneficial effects on bone marrow molecular alterations after myocardial infarction."
2.	Portal Hypertension 10/01/2009 - "Treating portal hypertension in cirrhotic rats with AVE 9488." 03/01/2008 - "We investigated whether the nitric oxide synthase (NOS) transcription enhancer AVE 9488 ameliorates portal hypertension in cirrhotic rats. " 03/01/2008 - "Treatment of bile duct-ligated rats with the nitric oxide synthase transcription enhancer AVE 9488 ameliorates portal hypertension."
3.	Ventricular Remodeling 08/19/2008 - "Improvement in left ventricular remodeling by the endothelial nitric oxide synthase enhancer AVE9488 after experimental myocardial infarction."
4.	Heart Failure 08/19/2008 - "Moreover, AVE9488 prevented the marked depression of circulating endothelial progenitor cell levels in rats with heart failure after MI. " 08/19/2008 - "In this study, we investigated whether the transcription enhancer of endothelial NO synthase (eNOS) AVE9488 improves cardiac remodeling and heart failure after experimental myocardial infarction (MI). "
5.	Neointima 05/01/2008 - "In apoE-KO mice, but not in eNOS-knockout mice, treatment with AVE9488 reduced cuff-induced neointima formation. "

Related Drugs and Biologics

1.	Nitric Oxide Synthase (NO Synthase)
2.	Nitric Oxide Synthase Type III (Endothelial Nitric Oxide Synthase)
3.	Brain Natriuretic Peptide (Natrecor)
4.	Endothelin-1 (Endothelin 1)
5.	Superoxides (Superoxide)
6.	Proteins (Proteins, Gene)
7.	Atrial Natriuretic Factor (ANF)
8.	Hydroxymethylglutaryl CoA Reductases (HMG CoA Reductase)
9.	Apolipoproteins E (ApoE)
10.	2,2- difluorobenzo(1,3)dioxole- 5- carboxylic acid indan-2-ylamide

Related Therapies and Procedures

1.	Ligation